Pidilizumab in Treating Patients With Stage III-IV Diffuse Large B-Cell Lymphoma Following First Remission

NCT02530125 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

4

Enrollment

OTHER

Sponsor class

Stopped sponsor decided to discontinue development of the study drug.

Conditions

Stage III Diffuse Large B-Cell Lymphoma
Stage IV Diffuse Large B-Cell Lymphoma

Interventions

OTHER: Laboratory Biomarker Analysis
BIOLOGICAL: Pidilizumab

Sponsor

Northwestern University

Collaborators

[object Object]
[object Object]